Journal Article Summary
The article investigates the effectiveness and safety of hormone therapies for treating pelvic pain associated with adenomyosis, a condition affecting many women of childbearing age. This topic is significant because adenomyosis can lead to chronic pelvic pain and other complications, severely impacting quality of life. Currently, there are no established guidelines for treating this condition, and many hormone treatments are used off-label, making it essential to evaluate their efficacy and safety.
The researchers conducted a systematic review and network meta-analysis of randomized controlled trials, including six studies with a total of 563 women diagnosed with adenomyosis. They found that dienogest, a type of hormone therapy, was the most effective treatment for reducing pelvic pain at both three and six months compared to other options like combined oral contraceptives and a levonorgestrel-based intrauterine system. While dienogest showed significant pain relief, it was also associated with a higher incidence of adverse effects compared to other treatments.
Despite the promising results, the study has limitations, including a small number of included trials and potential biases due to single-center designs. Patients should discuss these findings with their healthcare providers to weigh the benefits and risks of different hormone therapies, especially considering the potential for adverse effects. It is crucial for patients to have informed conversations about their treatment options, as individual responses to therapy can vary significantly.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Etrusco Andrea, Agrifoglio Vittorio, D’Amato Antonio, Chiantera Vito, Laganà Antonio Simone, Haydamous Joe, Cobellis Luigi, De Franciscis Pasquale, et al.. Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology 2025. DOI: 10.3389/fendo.2025.1571727. PMID: 40166680. PMCID: PMC11955467.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
